With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.
Step a) Intermediate 200 -[(4-Bromophenyl)sulfanyl]tetrahydro-2H-pyran To a solution of 4-bromobenzenethiol (2 g, 10.58 mmol) in DMF (20 ml) was added NaH (0.635 g, 15.87 mmol) at 0 C and the reaction stirred for 1 h. To this was added 4-bromotetrahydro-2H-pyran (1.92 g, 1 1.64 mmol) in DMF and the reaction allowed to warm to r.t. and stirred for 67 h. Reaction was quenched by addition of water and extracted with EtOAc (x 2). The organics were washed with brine (x 5), dried (MgSC>4) and concentrated under reduced pressure. The residue was purified by column chromatography (Si02; 0 -100 % DCM in petrol) to yield 4-[(4- bromophenyl)sulfanyl]tetrahydro-2H-pyran (2.18 g, 75 %). ? NMR (400 MHz, DMSO- ) 87.52 (ra, 2H), 7.35 (m, 2H), 3.73 – 3.88 (m, 2H), 3.44 – 3.56 (m, 1H), 3.39 (m, 2H), 1.84 (m, 2H), 1.49 (m, 2H)
25637-16-5, 25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; RUPRAH, Parminder, Kaur; MERCHANT, Kevin, John; WALSH, Louise, Marie; KERR, Catrina, Morven; FIELDHOUSE, Charlotte; HARRISSON, David; MAINE, Stephanie; HAZEL, Katherine; WO2013/27001; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics